CTOs on the Move


 
EXOS is a leader in the field of human performance, a category it created more than 15 years ago. Today, EXOS employs more than 3,500 people in over 400 locations worldwide. With award-winning facilities, technology, and services, EXOS helps people take control of their health and performance so they can achieve what matters most to them. EXOS is trusted by hundreds of clients, including one-quarter of Fortune 100 companies, world champions in sports, and leaders in health care, military, and community organizations.
  • Number of Employees: 1K-5K
  • Annual Revenue: $100-250 Million
  • www.teamexos.com
  • 2629 East Rose Garden Lane
    Phoenix, AZ USA 85050
  • Phone: 480.449.9000

Executives

Name Title Contact Details
Yvette Pasqua
Chief Technology Officer Profile
Thomas Glaser
Chief Information Security Officer Profile

Similar Companies

Condensed Curriculum International Inc

Condensed Curriculum International Inc is a Fairfield, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cardiva Medical

Cardiva Medical, Inc. is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Sunnyvale, CA. To find more information about Cardiva Medical, Inc., please visit www.cardivamedical.com

Tanita Corporation of America

Tanita Corporation of America, Inc. is a Arlington Heights, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Tampa YMCA

The Y is a leading nonprofit committed to strengthening community through youth development, healthy living, and social responsibility.

Dimension Therapeutics

Dimension Therapeutics, Inc. is a rare disease company focused on discovering and developing new therapeutic products for people living with devastating rare diseases associated with the liver and based on the most advanced adeno-associated virus (AAV) delivery technology. The company is advancing multiple programs toward clinical development, including: programs addressing unmet needs for patients suffering from OTC deficiency and GSDIa; a collaboration with Bayer HealthCare in hemophilia A, and a wholly owned program in hemophilia B, which is expected to enter clinical testing in the second half of 2015. Dimension has preferred access to multiple AAV vectors from REGENXBIO. The Dimension team and senior advisors include biotech industry veterans and renowned thought leaders in gene therapy and rare diseases.